Table 2.
Baseline characteristics
| Total number of patients n = 89 |
PET-CT n = 45 |
CE-CT n = 44 |
|
|---|---|---|---|
| Age, years | 65.3 (57.6-73.2) | 67.6 (59.8-74.5)* | 60.8 (56.6-70.1)* |
| Gender, female | 27 (30.3) | 16 (35.6) | 11 (25) |
| Adenocarcinoma | 57 (64) | 30 (66.7) | 27 (61.4) |
| NSCLC stage | |||
| I | 44 (49.4) | 21 (46.7) | 23 (52.3) |
| II | 24 (26.9) | 14 (31.1) | 10 (22.7) |
| III | 18 (20.2) | 8 (17.8) | 10 (22.7) |
| IVa | 3 (3.4) | 2 (4.4) | 1 (2.3) |
| Therapy | |||
| Surgery alone | 58 (65.2) | 31 (68.9) | 27 (61.4) |
| Surgery + adjuvant chemoth. | 19 (21.4) | 7 (15.6) | 12 (27.3) |
| Surgery + neoadjuvant chemoth. | 7 (7.8) | 4 (8.9) | 3 (6.8) |
| Radiotherapy +/- chemoth. | 2 (2.3) | 1 (2.2) | 1 (2.3) |
| Other | 3 (3.4) | 2 (4.4) | 1 (2.3) |
| Total number of surveillance studies | 266 | 129 | 137 |
Data presented as medians (IQRs) or numbers (%)
PET-CT integrated F-fluorodeoxyglucose positron emission tomography-computed tomography, CE-CT contrast-enhanced computed tomography, NSCLC non-small cell lung cancer
*p = 0.037 PET-CT vs. CE-CT
asolitary brain metastasis